You are here: Industry Insights > RedHill

News List

RedHill Biopharma Initiates Phase 3 Study of RHB-204 for First-Line Treatment of NTM Disease prnasia
November 23, 2020
RHB-204 is being evaluated as a first-line, stand-alone, oral treatment for pulmonary nontuberculous mycobacteria (NTM) disease - a rare condition with no FDA-approved first-line therapy.
RedHill Receives Patent Allowance Covering Opaganib, RHB-107 Combination americanpharmaceuticalreview
November 13, 2020
RedHill Biopharma has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a new patent application related to the use of two of RedHill’s proprietary investigational compounds, opaganib (Yeliva®, ABC294640) and ..
RedHill Announces Orphan Drug Designation for NTM Infection Treatment americanpharmaceuticalreview
October 22, 2020
RedHill Biopharma announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to RHB-204 for the treatment of nontuberculous mycobacteria (NTM) disease.
RedHill and Cosmo Pharmaceuticals Expand Strategic Partnership contractpharma
August 14, 2020
RedHill Biopharma Ltd., a specialty biopharmaceutical company, has entered into a binding term sheet with Cosmo Pharmaceuticals N.V. for an exclusive licensing and manufacturing agreement for multiple products.
RedHill Receives Approval for COVID-19 Phase 2/3 Study with Opaganib in UK americanpharmaceuticalreview
July 08, 2020
RedHill Biopharma announced the UK Medicines & Healthcare products Regulatory Agency (MHRA) has approved the Company’s Clinical Trial Authorization (CTA) application to commence a Phase 2/3 study evaluating opaganib (Yeliva®, ABC294640) ...
FDA Accepts RedHill Biopharma’s NDA for Talicia contractpharma
July 17, 2019
Commercial launch of H. pylori treatment is planned shortly following potential FDA approval.
RedHill Biopharma Submits New Drug Application for Talicia for H. pylori Infection drugs
May 17, 2019
RedHill Biopharma Submits New Drug Application for Talicia for H. pylori Infection.
RedHill Biopharma enrols last patient in Phase II irritable bowel syndrome trial europeanpharmaceuticalreview
May 07, 2019
RedHill Biopharma has enrolled the last patient in the Phase II study with Bekinda for the treatment of diarrhoea-predominant irritable bowel syndrome…
RedHill’s H. pylori antibiotic flies through phase 3, on track for 2019 launch fiercebiotech
January 02, 2019
RedHill Biopharma’s lead asset, antibiotic cocktail RHB-105, bested an amoxicillin combination in patients with H. pylori infection, topline phase 3 data show.....
RedHill Announces U.S. Co-Promotion Agreement with Napo Pharmaceuticals for HIV/AIDS Anti-Diarrheal Drug Mytesi pharmafocusasia
December 03, 2018
RedHill Biopharma Ltd., a speciality company primarily focused on late clinical-stage development and commercialization of proprietary drugs for gastrointestinal (GI) diseases...

Previous page 1 2 3 4 Next page